The TF group has recently published an EAACI Position Paper harmonizing current concepts of AECs and projecting unmet needs as a starting point.

Within this interdisciplinary Task Force Project the comparability of different AEC facilities with regards to validity of study results, technical principles and standards of the models will be evaluated and discussed . Besides this the group will elaborate the principle of a (multicenter, multinational) study design of a “hybrid”-trial in AIT more in detail which was highlighted by the TF as the most important need of further clinical validation. Again, this subsequent TF group activity will compass international scientists, clinicians, representatives from EMA and FDA and world wide AEC operators to implement all relevant stakeholders within this project and EAACI Position.

PHASE 3 Critical steps in 2021 (Phase 2): In earlier phase 1, our TF group has published an EAACI Position Paper harmonizing current concepts of AECs and projecting unmet needs as a starting point (Pfaar et al. 2017). Hereafter, several working groups have published validation data on different AEC models on the basis of the EAACI statements and positions. Based on this work, we have in 2021 published the first report of technical details and technical validation of all AECoperators/facilities worldwide (Phase 2 of the project-planning) (Pfaar et al. 2021) In the next phase (Phase 3, 2022), our interdisciplinary Task Force now aims to further elaborate a global Position of stakeholders in the field of AECs on the assessment measures used in different facilities. Again, this initiative aims to harmonize standards (SOPs) in AEC-design and this Position Paper in 2022 will be another step in reaching a broad consensus regarding validation of chamber models for clinical development programs in the field of allergic rhinitis and asthma.

IG Allergen Immunotherapy

Chair: Oliver Pfaar
Secretary: Petra Zieglmayer